Pharmaceuticals

Global Oral Antidiabetic Drugs Market 2026 accelerating toward $92.64 billion by 2030 at a 6.7% CAGR

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Oral Antidiabetic Drugs Market Across 2026–2030?

The market for oral antidiabetic drugs has experienced significant growth in recent years. The market is forecast to increase from $66.73 billion in 2025 to $71.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. This growth in prior periods has stemmed from the restricted availability of oral antidiabetic drug classes, a continued reliance on conventional biguanides and sulfonylureas, the rising incidence of type 2 diabetes, the expansion of hospital and pharmacy distribution networks, and increasing awareness of diabetes management.

The oral antidiabetic drugs market size is expected to experience significant growth in the coming years, with projections indicating it will reach $92.64 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.7%. This expansion during the forecast period can be attributed to the advancement of novel DPP-4 and SGLT2 inhibitors, the increasing availability of combination therapies, a rise in the adoption of personalized medicine approaches, the development of online pharmacy and telemedicine channels, and growing government initiatives aimed at diabetes care. Furthermore, prominent trends for this period include the increasing prevalence of type 2 diabetes, a greater uptake of combination oral antidiabetic drugs, the expansion of online and retail pharmacy channels, a heightened focus on individualized diabetes management, and improved awareness and educational efforts concerning diabetes care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25854&type=smp

Which Market Drivers Are Supporting The Expansion Of The Oral Antidiabetic Drugs Market?

The future expansion of the oral antidiabetic drugs market is anticipated to be driven by the rising incidence of type 2 diabetes. This chronic ailment, type 2 diabetes, involves the body’s inability to either respond effectively to insulin or generate sufficient amounts to sustain healthy glucose levels. The escalating prevalence of type 2 diabetes stems from growing obesity rates, given that surplus body fat leads to insulin resistance and compromised glucose control. Oral antidiabetic drugs assist in managing type 2 diabetes by boosting insulin sensitivity, promoting insulin secretion, or decreasing glucose creation and absorption, ultimately stabilizing blood sugar levels. For example, in March 2025, the Office for Health Improvement and Disparities, a UK-based government agency, reported that the prevalence of type 2 diabetes among adults aged 17 and above in England increased to 7.0%, an uptick from 6.8% recorded in March 2023. Consequently, the upward trend in type 2 diabetes is a significant driver for the expansion of the oral antidiabetic drugs market.

What Segmentation Levels Are Considered In The Oral Antidiabetic Drugs Market?

The oral antidiabetic drugs market covered in this report is segmented –

1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Sublingual, Buccal

3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels

5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users

Subsegments:

1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide

5) By Thiazolidinediones: Pioglitazone, Rosiglitazone

6) By Meglitinides: Repaglinide, Nateglinide

7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose

8) By Other Drug Classes: Bromocriptine, Colesevelam

What Trends Are Projected To Affect The Oral Antidiabetic Drugs Market?

Leading firms within the oral antidiabetic drugs market are prioritizing clinical research to innovate superior and safer therapeutic solutions, diversify their offerings, and secure regulatory clearances for advanced treatments. These studies, conducted under controlled conditions with human subjects, assess the security, potency, and adverse reactions of novel medical therapies, medications, or procedures. For instance, in April 2025, Eli Lilly and Company, a US-based pharmaceutical company, launched Orforglipron, an oral, once-daily, small-molecule GLP-1 receptor agonist intended to streamline diabetes care following a successful phase 3 trial. The oral treatment seeks to provide similar effectiveness and safety as injectable alternatives while simultaneously improving patient compliance. During these studies, orforglipron demonstrated a reduction in HbA1c (a marker of blood sugar control) by an average of 1.3% to 1.6% across varied dosages over 40 weeks.

Which Leading Firms Are Contributing To The Growth Of The Oral Antidiabetic Drugs Market?

Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

Read the full oral antidiabetic drugs market report here:

https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

How Is The Oral Antidiabetic Drugs Market Distributed Across Key Geographic Regions?

North America was the largest region in the oral antidiabetic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oral Antidiabetic Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25854&type=smp

Browse Through More Reports Similar to the Global Oral Antidiabetic Drugs Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795